Physician agency and adoption of generic pharmaceuticals

American Economic Review

Volumn 102, Issue 6, 2012, Pages 2826-2858

  Iizuka, Toshiaki ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GENERIC DRUG;

CLINICAL PRACTICE; HUMAN; JAPAN; MASS COMMUNICATION;

DIFFUSION OF INNOVATION; DRUGS, GENERIC; HUMANS; JAPAN; PRACTICE PATTERNS, PHYSICIANS';

EID: 84867711279     PISSN: 00028282     EISSN: None     Source Type: Journal    
DOI: 10.1257/aer.102.6.2826     Document Type: Review

References (38)

1. Afendulis, Christopher C., and Daniel P. Kessler. 2007. "Tradeoffs from Integrating Diagnosis and Treatment in Markets for Health Care." American Economic Review 97 (3): 1013-20.
2. Bartus, Támas. 2005. "Estimation of Marginal Effects Using Margeff." Stata Journal 5 (3): 309-29. (Pubitemid 43708466)
3. Beck, Melinda. 2008. "Inexact Copies: How Generics Differ from Brand Names." Wall Street Journal, April 22.
4. Caves, Richard E., Michael D. Whinston, Mark A. Hurwitz, Ariel Pakes, and Peter Temin. 1991. "Patent Expiration, Entry, and Competition in the U.S. Pharmaceutical Industry." Brookings Papers on Economic Activity 1-66.
5. Ching, Andrew T. 2010a. "Consumer Learning and Heterogeneity: Dynamics of Demand for Prescription Drugs after Patent Expiration." International Journal of Industrial Organization 28 (6): 619-38.
6. Ching, Andrew T. 2010b. "A Dynamic Oligopoly Structural Model for the Prescription Drug Market after Patient Expiration." International Economic Review 51 (4): 1175-207.
7. Congressional Budget Office. 2005. Payments for Prescription Drugs Under Medicaid: CBO Testimony Before the Special Committee on Aging, United States Senate. Statement of Douglas Holtz-Eakin, Director Congressional Budget Office. http://www.cbo.gov/ftpdocs/65xx/doc6564/07-20-MedicaidRx. pdf (accessed January 16, 2008).
8. Coscelli, Andrea. 2000. "The Importance of Doctors' and Patients' Preferences in the Prescription Decision." Journal of Industrial Economics 48 (3): 349-69.
9. Darby, Michael R., and Edi Karni. 1973. "Free Competition and the Optimal Amount of Fraud." Journal of Law and Economics 16 (1): 67-88.
10. Eggleston, Karen, ed. 2009. Prescribing Cultures and Pharmaceutical Policy in the Asia-Pacic. Palo Alto, CA: Walter H. Shorenstein Asia-Pacific Research Center.
11. Ellison, Sara Fisher, Iain Cockburn, Zvi Griliches, and Jerry Hausman. 1997. "Characteristics of Demand for Pharmaceutical Products: An Examination of Four Cephalosporins." RAND Journal of Economics 28 (3): 426-46. (Pubitemid 127346460)
12. Grabowski, Henry, and John Vernon. 1996. "Longer Patents for Increased Generic Competition in the US: The Waxman-Hatch Act after One Decade." PharmacoEconomics 10 (S2): 110-23.
13. Griliches, Zvi, and Iain Cockburn. 1994. "Generics and New Goods in Pharmaceutical Price Indexes." American Economic Review 84 (5): 1213-32.
14. Gruber, Jonathan, and Maria Owings. 1996. "Physician Financial Incentives and Cesarean Section Delivery." RAND Journal of Economics 27 (1): 99-123.
15. Guadagni, Peter M., and John D. C. Little. 1983. "A Logit Model of Brand Choice Calibrated on Scanner Data." Marketing Science 2 (3): 203-38.
16. Hellerstein, Judith K. 1998. "The Importance of the Physician in the Generic versus Trade-Name Prescription Decision." RAND Journal of Economics 29 (1): 108-36. (Pubitemid 128351561)
17. Heckman, James J. 1981. "The Incidental Parameters Problem and the Problem of Initial Conditions in Estimating a Discrete Time-Discrete Data Stochastic Process." In Structural Analysis of Discrete Data with Econometric Applications, edited by Charles F. Manski and Daniel L. McFadden, 179-95. Cambridge, MA: MIT Press.
18. Hubbard, Thomas N. 1998. "An Empirical Examination of Moral Hazard in the Vehicle Inspection Market." RAND Journal of Economics 29 (2): 406-26.
19. Iizuka, Toshiaki. 2007. "Experts' Agency Problems: Evidence from the Prescription Drug Market in Japan." RAND Journal of Economics 38 (3): 844-62.
20. Iizuka, Toshiaki. 2009. "Generic Entry in a Regulated Pharmaceutical Market." Japanese Economic Review 60 (1): 63-81.
21. Iizuka, Toshiaki. 2012. "Physician Agency and Adoption of Generic Pharmaceuticals: Dataset." American Economic Review. http://dx.doi.org/10. 1257/aer.102.6.2826.
22. Izumida, Nobuyuki, and Takeshi Yamada. 2002. "On the Status of Vertical Separation of Prescribing and Dispensing: A Study Using National Health Insurance Data." Unpublished.
23. Japan Medical Data Center (JMDC). 2003-2005. http://www.jmdc.co.jp/ (proprietary dataset).
24. Jiho Inc. 2003-2005. "Nihon Iyakuhin-syu Data Base." http://www.jiho.co.jp/cd/iyaku/index.html (proprietary dataset).
25. Keane, Michael P. 1997. "Modeling Heterogeneity and State Dependence in Consumer Choice Behavior." Journal of Business and Economic Statistics 15 (3): 310-27.
26. Levitt, Steven D., and Chad Syverson. 2008. "Market Distortions When Agents Are Better Informed: The Value of Information in Real Estate Transactions." Review of Economics and Statistics 90 (4): 599-611.
27. Liu, Ya-Ming, Yea-Huei Kao Yang, and Chee-Ruey Hsieh. 2009. "Financial Incentives and Physicians' Prescription Decisions on the Choice between Brand-Name and Generic Drugs: Evidence from Taiwan." Journal of Health Economics 28 (2): 341-49.
28. Lundin, Douglas. 2000. "Moral Hazard in Physician Prescription Behavior." Journal of Health Economics 19 (5): 639-62.
29. Regan, Tracy L. 2008. "Generic Entry, Price Competition, and Market Segmentation in the Prescription Drug Market." International Journal of Industrial Organization 26 (4): 930-48.
30. Reiffen, David, and Michael R. Ward. 2005. "Generic Drug Industry Dynamics." Review of Economics and Statistics 87 (1): 37-49.
31. Rivers, Douglas, and Quang H. Vuong. 1988. "Limited Information Estimators and Exogeneity Tests for Simultaneous Probit Models." Journal of Econometrics 39 (3): 347-66.
32. Scott Morton, Fiona M. 1999. "Entry Decisions in the Generic Pharmaceutical Industry." RAND Journal of Economics 30 (3): 421-40.
33. Simoens, Steven, and Sandra De Coster. 2006. Sustaining Generic Medicines Markets in Europe. Belgium: Research Center for Pharmaceutical Care and Pharmaco-economics.
34. Tomita, Naoko. 2009. "The Political Economy of Incrementally Separating Prescription from Dispensation in Japan." In Prescribing Cultures and Pharmaceutical Policy in the Asia-Pacific, edited by Karen Eggleston, 61-78. Palo Alto, CA: The Walter H. Shorenstein Asia-Pacific Research Center.
35. Villas-Boas, J. Miguel, and Russell S. Winer. 1999. "Endogeneity in Brand Choice Models." Management Science 45 (10): 1324-38.
36. Wooldridge, Jeffrey M. 2002a. "Simple Solutions to the Initial Conditions Problem in Dynamic, Nonlinear Panel Data Models with Unobserved Heterogeneity." Center for Microdata Methods and Practice (cemmap) Working Paper CWP18/02.
37. Wooldridge, Jeffrey M. 2002b. Econometric Analysis of Cross Section and Panel Data. Cambridge, MA: MIT Press.
38. Wooldridge, Jeffrey M. 2005. "Simple Solutions to the Initial Conditions Problem in Dynamic, Nonlinear Panel Data Models with Unobserved Heterogeneity." Journal of Applied Econometrics 20 (1): 39-54. (Pubitemid 40854807)